Oral mucositis induced by anticancer treatments: physiopathology and treatments
| Autor: | Canon Jean-Luc, André Marc, Lonchay Christophe, D'Hondt Lionel |
|---|---|
| Přispěvatelé: | UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, UCL - (MGD) Service d'hématologie |
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
Chemical Health and Safety Side effect business.industry Cancer Review General Medicine chemotherapy medicine.disease Pathophysiology Quality of life (healthcare) Palifermin Epidemiology Mucositis Medicine Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics business Complication Intensive care medicine palifermin Safety Research radiotherapy oral mucositis medicine.drug |
| Zdroj: | Therapeutics and Clinical Risk Management Therapeutics and clinical risk management, Vol. 2, no. 2, p. 159-68 (2006) |
| ISSN: | 1176-6336 |
| DOI: | 10.2147/tcrm.2006.2.2.159 |
| Popis: | Oral mucositis is a frequent and devastating side effect of anticancer treatments. It impairs the patient's quality of life and also can be life threatening because severe infections and delayed or incomplete anticancer treatments may result. This problem has been largely overlooked and underestimated in the past. However, recently studies have been performed to precisely identify the epidemiology, cost, consequences, physiopathology, and treatments of oral mucositis. Clinical guidelines have recently been published to help the daily management of this frequent complication. In addition, some innovative new drugs, including palifermin, have been developed to prevent and treat this major side effect of cancer treatments. In this paper we summarize the recent developments of oral mucositis management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|